235: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 1

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.In this episode, we cover:Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)Smart insight:The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: [email protected] Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show